[Clinical evaluation of XXXX in urinary tract and @entity1069 ].

@entity1 @entity104 @entity1712 @entity1069 @entity1910 @entity5609 @entity294 @entity5898 @entity5450 @entity281 @entity4005 @entity6278 @entity2885 @entity2335 @entity293 @entity526
@entity6278 , a new @entity5898 , was given to fifty @entity1 (28 male and 22 female) aged 15 to 86 years with @entity281 of the urinary tract or prostate. @entity293 , i.e. @entity2335 in 20 cases and @entity2885 in 21, were usually chronic and associated with @entity5450 . Nine @entity1 had @entity281 of the prostate. Pathogens recovered from the urine were 26 @entity526 , 8 @entity4005 , 16 Serratia, 5 @entity5609 or @entity104 -positive Proteus, 1 Providencia, and 4 Pseudomonas. Minimal inhibitory concentrations of @entity6278 ranged from 0.015 to 64 micrograms/ml (mean MIC: 0.12 micrograms/ml). @entity6278 was given as single drug therapy in all @entity1 but one, in a daily dosage of 2 g divided into two intramuscular injections, for 3 to 28 days (average 22 days). Follow-up after discontinuation of treatment was four weeks. Therapeutic results were as follows: 13 successes and 7 failures by relapse for the 20 @entity2335 @entity1 , 13 successes and 7 failures by relapse for the 20 interpretable cases of @entity2885 , and 4 successes and 5 failures by relapse for the 9 @entity1 with @entity1069 . Local tolerance was excellent. @entity1910 in 2 @entity1 and @entity294 in 1 required withdrawal of the drug. Three other @entity1 with @entity294 were able to continue treatment. Intolerance to ingestion of alcoholic beverages was reported by 10 @entity1 . @entity1712 was recorded in 2 cases and a transient mononucleosic reaction in one. No renal of hepatic side effects were documented.
